KALA BIO, INC. Long-Term Debt, Maturity, Year Five
KALA BIO, INC. (KALA) had Long-Term Debt, Maturity, Year Five of $22.22 million as of 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2022-03-29
- 2021-12-31: Long-Term Debt, Maturity, Year Five $22.22M.
- 2019-12-31: Long-Term Debt, Maturity, Year Five $25.00M.
- 2018-12-31: Long-Term Debt, Maturity, Year Five $33.33M.
- 2018-09-30: Long-Term Debt, Maturity, Year Five $1.67M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2021-12-31 | $22.22M 10-K · filed 2022-03-29 |
| 2019-12-31 | $25.00M 10-K · filed 2020-02-12 |
| 2018-12-31 | $33.33M 10-K · filed 2019-03-12 |
| 2018-09-30 | $1.67M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.67M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $1.67M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |